ServierVenture CapitalInside Servier’s new €200M venture fundWith the launch of Servier Ventures announced in January and a €200 million commitment to biotech investment, Servier is stepping up its engagement in early-stage innovation in oncology and neurology. … more ➔
Paris Bilal via Unsplash+AcquisitionChiesi in US$1.9bn deal to buy KalVista and its angioedema drugItalian pharma group Chiesi has struck a near‑US$1.9bn deal to acquire KalVista Pharmaceuticals, bringing the US biotech’s first‑in‑class oral treatment for hereditary angioedema into its rare‑disease … more ➔
A. C. via Unsplash+FinancingCoultreon bags US$125m for autoimmune pipelineBelgian Coultreon Biopharma has raised US$125m in a big‑pharma‑backed Series A round to push its first‑in‑class SIK3 inhibitor into Phase II after an ongoing Phase I programme in autoimmune … more ➔
Pic by masakazu sasaki via UnsplashAcquisitionAstorg spins off Thermo Fisher’s microbiology armPan-European private‑equity firm Astorg has agreed to acquire Thermo Fisher Scientific’s global microbiology business for about US$1.08bn, carving it out into a standalone platform focused on antimicrobial … more ➔
Andrej Lišakov / Unsplash+Covid-19CureVac takes Moderna to court over mRNA vaccine patentsCureVac has filed a federal lawsuit accusing Moderna of patent infringement over its mRNA-based COVID-19 vaccine Spikevax. The German biotech claims that Moderna used its proprietary methods for stabilising … more ➔
Evonik Industries AGInvestmentEvonik: €80m for biopharma CDMO capacity in SlovakiaEvonik is investing €80 million in its fermentation plant in Slovakia, pushing the Group’s structural transformation forward with a major investment in biotechnology. Alongside spider‑silk proteins … more ➔
Venture CapitalKurma Partners closes Biofund IV at €215M, giving European biotech a fresh specialist pool of capitalKurma Partners has closed Biofund IV at €215 million, giving European biotech founders a meaningful new source of capital even though the vehicle came in below the €250 million target Kurma set when … more ➔
Unsplash+Ovarian cancerEpitopea wins UK approval for therapeutic vaccine trialCryptiVax-1001 is set to enter first-in-human testing in advanced high-grade serous ovarian cancer, a setting with few durable treatment options. more ➔
Svitlana Hulko-freepik.comDeep DiveCan biotech finally fix infertility?According to the WHO, one adult in six globally is affected by infertility, but beyond this statistic, infertility is best understood as a couple’s problem, even when the underlying biology … more ➔
RochePhase IIIRoche’s fenebrutinib cuts relapses in MS amid safety concernsSwiss pharma giant Roche announced that its investigational BTK inhibitor fenebrutinib sharply reduced multiple sclerosis relapses in Phase III studies. However, death imbalances cloud the picture. more ➔
Servier
Paris Bilal via Unsplash+
A. C. via Unsplash+
Pic by masakazu sasaki via Unsplash
Andrej Lišakov / Unsplash+
Evonik Industries AG
Unsplash+
Svitlana Hulko-freepik.com
Roche